Sugi Predict

Sugi Predict / Compounds / SCHEMBL1623314

SCHEMBL1623314

SCHEMBL1623314

O=S(=O)(O)CCOCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.52
▸ CA1 P00915 2/20 0.46
▸ CA2 P00918 2/20 0.46
▸ CA9 Q16790 2/20 0.46
▸ CA7 P43166 1/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ HTT P42858 2/20 0.44
▸ MGLL Q99685 1/20 0.41
▸ TEAD3 Q99594 1/20 0.41
▸ LTA4H P09960 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.41
▸ LMNA P02545 2/20 0.41
▸ NAAA Q02083 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ MAPK1 P28482 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ SLC6A2 P23975 1/20 0.40
▸ SLC6A3 Q01959 1/20 0.40
▸ KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23462266 0.96 TSHR (0.48) TSHRCA1CA2CA9CA7
SCHEMBL7195587 0.89 TSHR (0.48) TSHRCA1CA2CA9CA7
SCHEMBL6598977 0.87 MGLL (0.49) TSHRCA1CA2CA9CA7
SCHEMBL27032244 0.86 TSHR (0.45) TSHRCA1CA2CA9CA7
SCHEMBL27032553 0.86 TSHR (0.45) TSHRCA1CA2CA9CA7
SCHEMBL12077051 0.86 TSHR (0.45) TSHRCA1CA2CA9CA7
SCHEMBL4435889 0.86 MGLL (0.48) TSHRCA1CA2CA9CA7
Hydrochloric Acid SCHEMBL28277924 0.84 MGLL (0.47) TSHRMGLLTEAD3LTA4HL3MBTL1
SCHEMBL27032524 0.84 MGLL (0.47) TSHRCA1CA2CA9CA7
SCHEMBL24486785 0.83 CA2 (0.50) TSHRCA1CA2CA9CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1027339-B1 METHOD AND REAGENTS FOR N-ALKYLATING UREIDES TARO PHARMA IND (IL) 2004-01-02 — — EP claimed
CN-115916777-B ATX inhibitor and preparation method and application thereof 苏州爱科百发生物医药技术有限公司 2024-07-12 — — CN disclosed
US-20230295159-A1 ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF SUZHOU ARK BIOPHARMACEUTICAL CO., LTD. (CN) 2023-09-21 — — US disclosed
US-20230295159-A1 ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF SUZHOU ARK BIOPHARMACEUTICAL CO., LTD. (CN) 2023-09-21 — — US disclosed
US-20230159477-A1 PROCESSES FOR PREPARING OXATHIAZIN-LIKE COMPOUNDS GEISTLICH PHARMA AG (CH) 2023-05-25 — — US disclosed
US-20230159477-A1 PROCESSES FOR PREPARING OXATHIAZIN-LIKE COMPOUNDS GEISTLICH PHARMA AG (CH) 2023-05-25 — — US disclosed
EP-4180430-A1 ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Suzhou Ark Biopharmaceutical Co., Ltd (CN) 2023-05-17 — — EP disclosed
EP-4180430-A1 ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Suzhou Ark Biopharmaceutical Co., Ltd (CN) 2023-05-17 — — EP disclosed
CN-115916777-A ATX inhibitor and preparation method and application thereof 苏州爱科百发生物医药技术有限公司 2023-04-04 — — CN disclosed
US-11591342-B2 Heterocyclic compound, application thereof and pharmaceutical composition comprising same Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) 2023-02-28 — — US disclosed
US-7928264-B2 Aminoalcohol derivatives ASTELLAS PHARMA INC. (JP) 2011-04-19 — — US disclosed
CN-101039902-B Aminoalcohol derivatives ASTELLAS PHARMA INC 2010-11-10 — — CN disclosed
EP-1791811-B1 AMINOALCOHOL DERIVATIVES ASTELLAS PHARMA INC (JP) 2009-12-23 — — EP disclosed
US-20080261973-A1 Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors NOVARTIS AG (CH) 2008-10-23 — — US disclosed
EP-1966210-A2 SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS Novartis AG (CH) 2008-09-10 — — EP disclosed
US-20080039506-A1 Aminoalcohol Derivatives ASTELLAS PHARMA INC. (JP) 2008-02-14 — — US disclosed
CN-101039902-A Aminoalcohol derivatives ASTELLAS PHARMA INC (JP) 2007-09-19 — — CN disclosed
WO-2007071393-A2 SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS NOVARTIS AG (CH) 2007-06-28 — — WO disclosed
EP-1791811-A1 AMINOALCOHOL DERIVATIVES Astellas Pharma Inc. (JP) 2007-06-06 — — EP disclosed
WO-2006033446-A1 AMINOALCOHOL DERIVATIVES ASTELLAS PHARMA INC. (JP) 2006-03-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11591342-B2 Heterocyclic compound, application thereof and pharmaceutical composition comprising same ENPP2, ATXN10, PCSK9 TSHR 2363/4885CA1 808/4885CA2 434/4885
US-20230159477-A1 PROCESSES FOR PREPARING OXATHIAZIN-LIKE COMPOUNDS OXA1L, MAPT, OTC TSHR 2938/4885CA1 4841/4885CA2 4761/4885
US-20230295159-A1 ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF ATXN10, GCG, ATXN2L TSHR 1155/4885CA1 2474/4885CA2 2629/4885
US-20080261973-A1 Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors GRK4, JAK2, ALK TSHR 98/4885CA1 3227/4885CA2 2347/4885
US-20080039506-A1 Aminoalcohol Derivatives HRH4, HRH2, CBR3 TSHR 2359/4885CA1 3247/4885CA2 1296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.